Alternative Data for Genmab A/S
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 155 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 94,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,082 | Sign up | Sign up | Sign up |
| X Followers | 7,953 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 460 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 78 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,768 | Sign up | Sign up | Sign up |
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
| Price | $26.57 |
| Target Price | Sign up |
| Volume | 1,348,113 |
| Market Cap | $17.2B |
| Year Range | $20.3 - $35.34 |
| Dividend Yield | 0% |
| PE Ratio | 18.16 |
| Analyst Rating | 43% buy |
| Industry | Biotechnology |
In the news
 |
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP InvestmentFebruary 19 - ChartMill |
 |
Genmab A/S (GMAB) Q4 2025 Earnings Call TranscriptFebruary 17 - SeekingAlpha |
|
Genmab A/S 2025 Q4 - Results - Earnings Call PresentationFebruary 16 - SeekingAlpha |
 |
Is Genmab (CPSE:GMAB) Attractively Priced After Recent Share Price Pullback?February 10 - Yahoo |
|
Where is Genmab A/S (GMAB) Headed According to Wall Street?February 9 - Yahoo |
 |
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech GrowthFebruary 5 - ChartMill |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 1.02B | 58M | 964M | 401M | 503M | 0.650 |
| Q2 '25 | 5.86B | 361M | 5.5B | 2.13B | 2.84B | 0.540 |
| Q1 '25 | 715M | 42M | 673M | 195M | 265M | 0.310 |
| Q4 '24 | 6.44B | 337M | 6.1B | 3.85B | 2.36B | 0.840 |
| Q3 '24 | 5.54B | 273M | 5.27B | 1.27B | 2.2B | 0.290 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Josh Gottheimer |
Feb 11, 25 | Buy | $1K - $15K |
| Josh Gottheimer |
Jan 15, 25 | Sell | $1K - $15K |
| Josh Gottheimer |
Aug 15, 24 | Buy | $1K - $15K |
Read more about Genmab A/S (GMAB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Genmab A/S
The Market Cap of Genmab A/S is $17.2B.
As of today, Genmab A/S's PE (Price to Earnings) ratio is 18.16.
Currently, the price of one share of Genmab A/S stock is $26.57.
The GMAB stock price chart above provides a comprehensive visual representation of Genmab A/S's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Genmab A/S shares. Our platform offers an up-to-date GMAB stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Genmab A/S (GMAB) does not offer dividends to its shareholders. Investors interested in Genmab A/S should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Genmab A/S are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
